Isofol Medical (Sweden) Top Management
ISOFOL Stock | SEK 1.87 0.07 3.89% |
Isofol Medical employs about 15 people. The company is managed by 14 executives with a total tenure of roughly 58 years, averaging almost 4.0 years of service per executive, having 1.07 employees per reported executive. Analysis of Isofol Medical's management performance can provide insight into the company performance.
Jarl Jungnelius CEO Chief Executive Officer, Director |
ParOla Mannefred Chairman Chairman of the Board |
Isofol |
Isofol Medical Management Team Effectiveness
The company has return on total asset (ROA) of (0.3605) % which means that it has lost $0.3605 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.6945) %, meaning that it generated substantial loss on money invested by shareholders. Isofol Medical's management efficiency ratios could be used to measure how well Isofol Medical manages its routine affairs as well as how well it operates its assets and liabilities.Isofol Medical Workforce Comparison
Isofol Medical AB is rated fifth overall in number of employees category among its peers. The total workforce of Biotechnology industry is currently estimated at about 148. Isofol Medical retains roughly 15.0 in number of employees claiming about 10% of stocks in Biotechnology industry.
Isofol Medical AB Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Isofol Medical AB Price Series Summation is a cross summation of Isofol Medical price series and its benchmark/peer.
Isofol Medical Notable Stakeholders
An Isofol Medical stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Isofol Medical often face trade-offs trying to please all of them. Isofol Medical's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Isofol Medical's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Jarl Jungnelius | Chief Executive Officer, Director | Profile | |
ParOla Mannefred | Chairman of the Board | Profile | |
Gustaf Albert | Chief Financial Officer | Profile | |
Magnus Bjorsne | Director | Profile | |
Karin Ganlov | Senior Medical Director | Profile | |
Paula Boultbee | Director | Profile | |
Anna Belfrage | Director | Profile | |
Robert Marchesani | Director | Profile | |
Alain Herrera | Director | Profile | |
Gustaf MSc | CFO CEO | Profile | |
Roger Tell | Chief Medical Officer, Chief Scientific Officer | Profile | |
Jarl MD | CEO MD | Profile | |
Roger MD | Chief Officer | Profile | |
Jenny Sundqvist | Chief Officer | Profile |
About Isofol Medical Management Performance
The success or failure of an entity such as Isofol Medical AB often depends on how effective the management is. Isofol Medical management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Isofol management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Isofol management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Isofol Medical AB , a clinical stage biotech company, develops, commercializes, and sells oncology drugs in Sweden and internationally. The company was incorporated in 2008 and is headquartered in Gothenburg, Sweden. Isofol Medical operates under Biotechnology classification in Sweden and is traded on Stockholm Stock Exchange. It employs 12 people.
Please note, the presentation of Isofol Medical's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Isofol Medical's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Isofol Medical's management manipulating its earnings.
Isofol Medical Workforce Analysis
Traditionally, organizations such as Isofol Medical use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Isofol Medical within its industry.Isofol Medical Manpower Efficiency
Return on Isofol Medical Manpower
Revenue Per Employee | 1.5M | |
Revenue Per Executive | 1.6M | |
Net Loss Per Employee | 13.4M | |
Net Loss Per Executive | 14.3M |
Complementary Tools for Isofol Stock analysis
When running Isofol Medical's price analysis, check to measure Isofol Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Isofol Medical is operating at the current time. Most of Isofol Medical's value examination focuses on studying past and present price action to predict the probability of Isofol Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Isofol Medical's price. Additionally, you may evaluate how the addition of Isofol Medical to your portfolios can decrease your overall portfolio volatility.
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Bonds Directory Find actively traded corporate debentures issued by US companies |